Paper Details

  1. Home
  2. Paper Details

Haloperidol versus placebo for schizophrenia.

Author: AdamsClive E, BergmanHanna, IrvingClaire B, LawrieStephen

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Meta-AnalysisA statistical technique that integrates the results of multiple studies to draw more general conclusions about a particular issue.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.
Systematic ReviewA review that systematically collects, evaluates, and integrates relevant research to answer a specific research question.

Overview

Haloperidol is a potent antipsychotic drug that can be used to treat schizophrenia and other serious mental illnesses. It has a high propensity to cause adverse effects such as parkinsonism, akathisia, and acute dystonias. It is most effective in the first 6 weeks of treatment, but many people do not complete the short trials. While haloperidol is justified when there is no other treatment option, other antipsychotics with less likelihood of adverse effects may be preferred when available.
Paper Details　
Original Abstract of the Article :
BACKGROUND: Haloperidol was developed in the late 1950s for use in the field of anaesthesia. Research subsequently demonstrated effects on hallucinations, delusions, aggressiveness, impulsiveness and states of excitement and led to the introduction of haloperidol as an antipsychotic. OBJECTIVES: To...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1002/14651858.CD003082.pub3

データ提供：米国国立医学図書館（NLM）

Haloperidol: A Double-Edged Sword in Schizophrenia Treatment

Navigating the complex landscape of mental health is a challenge, and schizophrenia, a disorder that can create a mental desert, poses a significant hurdle. This research embarks on a journey through the effectiveness of haloperidol, a drug that has been a mainstay in schizophrenia treatment for decades, but also comes with its own set of challenges. This research aimed to evaluate the effectiveness of haloperidol in comparison to placebo in treating patients with schizophrenia.

A Double-Edged Sword: Benefits and Risks

The research found that haloperidol significantly improved symptoms of schizophrenia compared to placebo, which is like finding an oasis in the mental desert, offering relief from the debilitating symptoms. However, the study also showed that haloperidol has a high propensity to cause adverse effects, like a desert oasis that can also be a breeding ground for sandstorms. The authors caution that while haloperidol is effective in treating schizophrenia, alternatives with fewer adverse effects should be considered.

Navigating the Treatment Landscape: Finding the Right Path

The researchers advocate for careful consideration of the potential risks and benefits of haloperidol in individual patients. While it can be a valuable tool in the treatment of schizophrenia, its use should be approached with caution and an understanding of its potential for adverse effects. In the desert of mental illness, finding the right path requires careful navigation, considering both the potential benefits and the risks involved.

Dr.Camel's Conclusion

Treating schizophrenia is a complex task, but this research sheds light on the effectiveness of haloperidol. While haloperidol can offer significant relief from symptoms, its use should be weighed against the potential for adverse effects. It's like navigating a desert landscape, where the oasis of relief may also harbor potential dangers. Finding the right path for each patient is crucial, and this research provides valuable insight for navigating this complex terrain.

Date :
  1. Date Completed 2014-05-20
  2. Date Revised 2022-01-29
Further Info :

Pubmed ID

24242360

DOI: Digital Object Identifier

10.1002/14651858.CD003082.pub3

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.